TOP > 外国特許検索 > ADULT T-CELL LEUKEMIA-LYMPHOMA DETECTION METHOD

ADULT T-CELL LEUKEMIA-LYMPHOMA DETECTION METHOD NEW

外国特許コード F200010236
整理番号 (S2019-0201-N0)
掲載日 2020年10月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2020JP008206
国際公開番号 WO2020179646
国際出願日 令和2年2月28日(2020.2.28)
国際公開日 令和2年9月10日(2020.9.10)
優先権データ
  • 特願2019-037246 (2019.3.1) JP
発明の名称 (英語) ADULT T-CELL LEUKEMIA-LYMPHOMA DETECTION METHOD NEW
発明の概要(英語) An adult T-cell leukemia-lymphoma (ATL) detection method is provided which involves determining the presence or absence in a target biological sample of DNA methylation of at least one gene selected from the group consisting of SERPINB6, NELL2, THEMIS, ZSCAN18, LAIR1, CD7, RNF130, ZIK1, LYPD3, TMEM45B, POMC, FHIT, MDS2, HOOK1, SORCS3, C2orf40, ZNF662, SPG20, ZNF717, LZTFL1, KLHL34 and BCL9, wherein DNA methylation of at least one of the aforementioned genes indicates that the subject has developed or is at risk of developing ATL. By this means, a new detection method of adult T cell leukemia-lymphoma (ATL) is provided.
従来技術、競合技術の概要(英語) BACKGROUND ART
Adult T cell leukemia/lymphoma (ATL) is a peripheral T cell tumor caused by infection of T cells with retrovirus Human T-cell Lymphotropic Virus type-1 (HTLV-1). HTLV-1 is mainly infected by lactation, sex, transfusion, and the like, and HTLV-1 infants are localized in Japan, Calib sea coastal countries, central Africa, South America, and the like, and are estimated to be 500 million persons and ~ 2,000 million persons as a whole. HTLV-1 infectants in Japan are estimated to be 110 million, and (non-patent documents 1) and 40 ~ 50 % are unevenly distributed in Kyushu and okinawa district, but in recent years, HTLV-1 infectants in metropolitan areas such as Osaka, Tokyo and Aichi tend to increase.
HTLV-1-infected T cells undergo a multistage carcinogenesis process, which acquires clonic proliferation ability while accumulating genetic mutations and epigenetic abnormalities. Therefore, (Non-Patent Document 1) is characterized in that the period from infection to onset of ATL is very long, and as a result, there are many ATL onset persons in elderly carriers. On the other hand, most of HTLV-1 infected patients end their life as asymptomatic infected patients, but 3 ~ 5 % of infected patients develop ATL, and their clinical pathologies are classified into sod, chronic, acute and lymphoma types. Acute and lymphoma types and some chronic types having poor prognosis factors have high malignancy and very poor prognosis. On the other hand, the chronic type which does not have the poor prognosis factor is considered to be low grade ATL which follows relatively slow progress, and direct therapeutic intervention is not basically performed. However, (Non-Patent Document 2), in which approximately half of the low grade ATL patients have acute conversion over the course and the long-term prognosis thereof is poor. Therefore, it is desired to develop effective methods for preventing and treating ATL onset.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAGA UNIVERSITY
  • OHARA PHARMACEUTICAL CO., LTD.
  • 発明者(英語)
  • WATANABE Tatsuro
  • SUEOKA Eizaburo
  • KIMURA Shinya
  • URESHINO Hiroshi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は,下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close